Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04878029 |
|
Recruitment Status :
Recruiting
First Posted : May 7, 2021
Last Update Posted : August 10, 2022
|
Sponsor:
Emory University
Collaborators:
Exelixis
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Mehmet Bilen, Emory University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | January 21, 2025 |
| Estimated Study Completion Date : | January 21, 2025 |